Hasil Pencarian - Michel Clanet

  • Menampilkan 1 - 4 hasil dari 4
Perbaiki Hasil
  1. 1
    A case report of simultaneous PML-IRIS during corticosteroids tapering in a patient with an anti-synthetase syndrome [v1; ref status: indexed, http://f1000r.es/2l6]

    A case report of simultaneous PML-IRIS during corticosteroids tapering in a patient with an anti-synthetase syndrome [v1; ref status: indexed, http://f1000r.es/2l6] oleh Guillaume Martin-Blondel, David Brassat, Hervé Dumas, Emmanuelle Uro-Coste, Daniel Adoue, Hans Lassmann, Michel Clanet

    Diterbitkan 2013-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Geographical Heterogeneity of Multiple Sclerosis Prevalence in France.

    Geographical Heterogeneity of Multiple Sclerosis Prevalence in France. oleh Diane Pivot, Marc Debouverie, Michel Grzebyk, David Brassat, Michel Clanet, Pierre Clavelou, Christian Confavreux, Gilles Edan, Emmanuelle Leray, Thibault Moreau, Sandra Vukusic, Guy Hédelin, Francis Guillemin

    Diterbitkan 2016-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.

    Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. oleh Emmanuelle Leray, Sandra Vukusic, Marc Debouverie, Michel Clanet, Bruno Brochet, Jérôme de Sèze, Hélène Zéphir, Gilles Defer, Christine Lebrun-Frenay, Thibault Moreau, Pierre Clavelou, Jean Pelletier, Eric Berger, Philippe Cabre, Jean-Philippe Camdessanché, Shoshannah Kalson-Ray, Christian Confavreux, Gilles Edan

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

    MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of m... oleh Antonio Uccelli, Alice Laroni, Lou Brundin, Michel Clanet, Oscar Fernandez, Seyed Massood Nabavi, Paolo A. Muraro, Roberto S. Oliveri, Ernst W. Radue, Johann Sellner, Per Soelberg Sorensen, Maria Pia Sormani, Jens Thomas Wuerfel, Mario A. Battaglia, Mark S. Freedman, on behalf of the MESEMS study group

    Diterbitkan 2019-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: